Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04831047 · ClinicalTrials.gov registry record · Phase 4
The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance
A Phase 4 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 4
- Development phase
- 114
- Enrollment target
NCT04831047 is a Phase 4 study that has completed, run by University of Miami. The registered enrollment target is 114 participants.
The verdict
NCT04831047, a Phase 4 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 114 participants
- Enrollment target
Study Summary
The purpose of the research is to see if Upneeq ( oxymetazoline 0.1% ophthalmic solution) has an effect on eyelid position, eye redness, or patient-perceived appearance of the eyes.
Interventions
- DRUG Placebo
- DRUG Oxymetazoline hydrochloride 0.1% ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2022-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04831047
The ClinicalTrials.gov registry entry for NCT04831047 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04831047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04831047 about?
NCT04831047 is a clinical study titled "The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance". The purpose of the research is to see if Upneeq ( oxymetazoline 0.1% ophthalmic solution) has an effect on eyelid position, eye redness, or patient-perceived appearance of the eyes.
What is the current status of trial NCT04831047?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 114 participants. The study started on 2021-06-08. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT04831047?
The interventions under investigation include: Placebo (DRUG), Oxymetazoline hydrochloride 0.1% ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT04831047?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.